Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3 ...
Pharmacokinetics of cetuximab and tumor uptake of 89Zr-cetuximab as potential predictive biomarkers for benefit of cetuximab in patients with advanced colorectal cancer. This is an ASCO Meeting ...
Plasma cell leukemia (PCL) is a rare, aggressive subtype of multiple myeloma. Between 1973 and 2009, it’s estimated that PCL made up 0.6 percent of multiple myeloma diagnoses in the United States.
We conducted a randomized trial with a 2-by-2 factorial design to evaluate the use of plasma exchange and two regimens of oral glucocorticoids in patients with severe ANCA-associated vasculitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results